Literature DB >> 27154393

Hendra virus and Nipah virus animal vaccines.

Christopher C Broder1, Dawn L Weir2, Peter A Reid3.   

Abstract

Hendra virus (HeV) and Nipah virus (NiV) are zoonotic viruses that emerged in the mid to late 1990s causing disease outbreaks in livestock and people. HeV appeared in Queensland, Australia in 1994 causing a severe respiratory disease in horses along with a human case fatality. NiV emerged a few years later in Malaysia and Singapore in 1998-1999 causing a large outbreak of encephalitis with high mortality in people and also respiratory disease in pigs which served as amplifying hosts. The key pathological elements of HeV and NiV infection in several species of mammals, and also in people, are a severe systemic and often fatal neurologic and/or respiratory disease. In people, both HeV and NiV are also capable of causing relapsed encephalitis following recovery from an acute infection. The known reservoir hosts of HeV and NiV are several species of pteropid fruit bats. Spillovers of HeV into horses continue to occur in Australia and NiV has caused outbreaks in people in Bangladesh and India nearly annually since 2001, making HeV and NiV important transboundary biological threats. NiV in particular possesses several features that underscore its potential as a pandemic threat, including its ability to infect humans directly from natural reservoirs or indirectly from other susceptible animals, along with a capacity of limited human-to-human transmission. Several HeV and NiV animal challenge models have been developed which have facilitated an understanding of pathogenesis and allowed for the successful development of both active and passive immunization countermeasures. Published by Elsevier Ltd.

Entities:  

Keywords:  Animal models; Antiviral; Hendra; Henipavirus; Monoclonal antibody; Nipah; Paramyxovirus; Pathogenesis; Vaccine

Mesh:

Substances:

Year:  2016        PMID: 27154393      PMCID: PMC4933500          DOI: 10.1016/j.vaccine.2016.03.075

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  140 in total

1.  Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies.

Authors:  Zhongyu Zhu; Antony S Dimitrov; Katharine N Bossart; Gary Crameri; Kimberly A Bishop; Vidita Choudhry; Bruce A Mungall; Yan-Ru Feng; Anil Choudhary; Mei-Yun Zhang; Yang Feng; Lin-Fa Wang; Xiaodong Xiao; Bryan T Eaton; Christopher C Broder; Dimiter S Dimitrov
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

2.  A guinea-pig model of Hendra virus encephalitis.

Authors:  M M Williamson; P T Hooper; P W Selleck; H A Westbury; R F Slocombe
Journal:  J Comp Pathol       Date:  2001-05       Impact factor: 1.311

3.  Protein structure prediction on the Web: a case study using the Phyre server.

Authors:  Lawrence A Kelley; Michael J E Sternberg
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

4.  Urban habituation, ecological connectivity and epidemic dampening: the emergence of Hendra virus from flying foxes (Pteropus spp.).

Authors:  Raina K Plowright; Patrick Foley; Hume E Field; Andy P Dobson; Janet E Foley; Peggy Eby; Peter Daszak
Journal:  Proc Biol Sci       Date:  2011-05-11       Impact factor: 5.349

5.  Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus.

Authors:  H A Westbury; P T Hooper; P W Selleck; P K Murray
Journal:  Aust Vet J       Date:  1995-07       Impact factor: 1.281

6.  Late presentation of Nipah virus encephalitis and kinetics of the humoral immune response.

Authors:  S C Wong; M H Ooi; M N Wong; P H Tio; T Solomon; M J Cardosa
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-10       Impact factor: 10.154

Review 7.  Henipavirus outbreaks to antivirals: the current status of potential therapeutics.

Authors:  Christopher C Broder
Journal:  Curr Opin Virol       Date:  2012-03-21       Impact factor: 7.090

8.  A novel morbillivirus pneumonia of horses and its transmission to humans.

Authors:  K Murray; R Rogers; L Selvey; P Selleck; A Hyatt; A Gould; L Gleeson; P Hooper; H Westbury
Journal:  Emerg Infect Dis       Date:  1995 Jan-Mar       Impact factor: 6.883

9.  Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells.

Authors:  N W Gale; P Baluk; L Pan; M Kwan; J Holash; T M DeChiara; D M McDonald; G D Yancopoulos
Journal:  Dev Biol       Date:  2001-02-15       Impact factor: 3.582

Review 10.  Hendra virus: an emerging paramyxovirus in Australia.

Authors:  Suresh Mahalingam; Lara J Herrero; E Geoffrey Playford; Kirsten Spann; Belinda Herring; Michael S Rolph; Deborah Middleton; Bradley McCall; Hume Field; Lin-Fa Wang
Journal:  Lancet Infect Dis       Date:  2012-08-24       Impact factor: 25.071

View more
  27 in total

1.  Nipah and Hendra Virus Glycoproteins Induce Comparable Homologous but Distinct Heterologous Fusion Phenotypes.

Authors:  Birgit G Bradel-Tretheway; J Lizbeth Reyes Zamora; Jacquelyn A Stone; Qian Liu; Jenny Li; Hector C Aguilar
Journal:  J Virol       Date:  2019-06-14       Impact factor: 5.103

Review 2.  Receptor-mediated cell entry of paramyxoviruses: Mechanisms, and consequences for tropism and pathogenesis.

Authors:  Chanakha K Navaratnarajah; Alex R Generous; Iris Yousaf; Roberto Cattaneo
Journal:  J Biol Chem       Date:  2020-01-16       Impact factor: 5.157

3.  Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus.

Authors:  Michael K Lo; Franck Amblard; Mike Flint; Payel Chatterjee; Mahesh Kasthuri; Chengwei Li; Olivia Russell; Kiran Verma; Leda Bassit; Raymond F Schinazi; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2020-01-11       Impact factor: 5.970

Review 4.  Transmission of henipaviruses.

Authors:  Sarah Weatherman; Heinz Feldmann; Emmie de Wit
Journal:  Curr Opin Virol       Date:  2017-10-14       Impact factor: 7.090

Review 5.  Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.

Authors:  Katie Ewer; Sarah Sebastian; Alexandra J Spencer; Sarah Gilbert; Adrian V S Hill; Teresa Lambe
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

Review 6.  Vaccines for epidemic infections and the role of CEPI.

Authors:  Stanley A Plotkin
Journal:  Hum Vaccin Immunother       Date:  2017-04-04       Impact factor: 3.452

Review 7.  Influenza virus glycoprotein-reactive human monoclonal antibodies.

Authors:  Yanbai Li; Lili Wang; Helong Si; Zhengsen Yu; Shijun Tian; Rong Xiang; Xiaoqian Deng; Ruiying Liang; Shibo Jiang; Fei Yu
Journal:  Microbes Infect       Date:  2020-06-19       Impact factor: 2.700

8.  A recombinant Cedar virus based high-throughput screening assay for henipavirus antiviral discovery.

Authors:  Moushimi Amaya; Han Cheng; Viktoriya Borisevich; Chanakha K Navaratnarajah; Roberto Cattaneo; Laura Cooper; Terry W Moore; Irina N Gaisina; Thomas W Geisbert; Lijun Rong; Christopher C Broder
Journal:  Antiviral Res       Date:  2021-05-30       Impact factor: 10.103

Review 9.  Cryptic etiopathological conditions of equine nervous system with special emphasis on viral diseases.

Authors:  Rakesh Kumar; Rajendra D Patil
Journal:  Vet World       Date:  2017-12-10

10.  Rescue and characterization of recombinant cedar virus, a non-pathogenic Henipavirus species.

Authors:  Eric D Laing; Moushimi Amaya; Chanakha K Navaratnarajah; Yan-Ru Feng; Roberto Cattaneo; Lin-Fa Wang; Christopher C Broder
Journal:  Virol J       Date:  2018-03-27       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.